Literature DB >> 12297589

How often are nonenhancing supratentorial gliomas malignant? A population study.

J N Scott1, P M A Brasher, R J Sevick, N B Rewcastle, P A Forsyth.   

Abstract

The presence of contrast enhancement in a brain tumor is often regarded as a sign of malignancy. The authors identified 314 patients with malignant and low-grade supratentorial glial neoplasms in an unselected population, 58 of which lacked contrast enhancement on preoperative neuroimaging. Nonenhancing gliomas were malignant in approximately one third of cases, especially in older patients. Histologic confirmation of the diagnosis is therefore important in all patients suspected of harboring a primary glial neoplasm.

Entities:  

Mesh:

Year:  2002        PMID: 12297589     DOI: 10.1212/wnl.59.6.947

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  117 in total

1.  The dilemma of low grade glioma.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

3.  Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.

Authors:  Michail Plotkin; C Blechschmidt; G Auf; F Nyuyki; L Geworski; T Denecke; W Brenner; F Stockhammer
Journal:  Eur Radiol       Date:  2010-06-03       Impact factor: 5.315

4.  Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Authors:  Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

5.  Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Authors:  Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

6.  Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum.

Authors:  Jiaxuan Zhang; Wenzhen Zhu; Rongwen Tain; Xiaohong Joe Zhou; Kejia Cai
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 7.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

Review 8.  Clinical and research applications of simultaneous positron emission tomography and MRI.

Authors:  F Fraioli; S Punwani
Journal:  Br J Radiol       Date:  2013-11-14       Impact factor: 3.039

9.  High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging.

Authors:  Italo Aprile; Giorgia Giovannelli; Paola Fiaschini; Marco Muti; Anna Kouleridou; Nevia Caputo
Journal:  Radiol Med       Date:  2015-03-12       Impact factor: 3.469

10.  Non-enhancing de novo glioblastoma: report of two cases.

Authors:  Aaron A Cohen-Gadol; Michael L DiLuna; Sergei I Bannykh; Joseph M Piepmeier; Dennis D Spencer
Journal:  Neurosurg Rev       Date:  2004-07-28       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.